A Phase III, Two-Stage, Randomized Study of Mezigdomide, Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Relapsed/ Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）
关键词
RRMM, clinical trial, Phase III, trial in progress, CELMoDs
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要